IVBXF (Innovent Biologics) Goodwill-to-Asset: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBXF Innovent Biologics Inc IVBXF
71 GF Score
Price $12.53
GF Value $13.96
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Innovent Biologics's Goodwill for the quarter that ended in Jun. 2026 was $ Mil. Innovent Biologics's Total Assets for the quarter that ended in Jun. 2026 was $6,133 Mil. Therefore, Innovent Biologics's Goodwill to Asset Ratio for the quarter that ended in Jun. 2026 was .


Innovent Biologics  (OTCPK:IVBXF) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Innovent Biologics Goodwill-to-Asset Related Terms


Innovent Biologics Goodwill-to-Asset Historical Data

* Premium members only.

The historical data trend for Innovent Biologics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics Goodwill-to-Asset Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Innovent Biologics Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -

IVBXF vs VRTX, REGN, MRNA: Goodwill-to-Asset Comparison

For the Biotechnology subindustry, Innovent Biologics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics Goodwill-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Goodwill-to-Asset falls into.


IVBXF
71GF Score
Innovent Biologics Inc IVBXF
Goodwill-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovent Biologics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Innovent Biologics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Goodwill to Asset (A: Dec. 2025 )=Goodwill/Total Assets
=0/5344.4529668081
=0.00

Innovent Biologics's Goodwill to Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

Goodwill to Asset (Q: Jun. 2026 )=Goodwill/Total Assets
=/6133.2643617178
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Innovent Biologics (IVBXF) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of $12.53 is trading 10.2% below its estimated GF Value™ of $13.96. GuruFocus considers Innovent Biologics to be Modestly Undervalued.

Key valuation signals for IVBXF:

  • Goodwill-to-Asset:
  • GF Value™: $13.96 vs. price of $12.53 (10.2% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
71GF Score

Get the complete analysis for IVBXF

Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.53
Price
$13.96
GF Value